Short answer: Xeljanz (tofacitinib) or Xeljanz XR is not approved for alopecia areata. Some doctors have used JAK inhibitors off-label for AA, but this is not an FDA-approved indication for tofacitinib. Another JAK inhibitor, baricitinib (Olumiant), has FDA approval for alopecia areata in adults, so there are approved options in that class, but not tofacitinib.
What to know if someone is considering this
- What the evidence shows
- AA is driven by an autoimmune attack on hair follicles, and JAK inhibitors can reduce that immune activity.
- There are case reports and small studies suggesting hair regrowth in some people with AA on JAK inhibitors, including tofacitinib in some cases, but results vary and not everyone responds.
- Tofacitinib (Xeljanz) and the XR version are not officially approved for AA. Baricitinib has an approved indication for AA in adults in some regions (FDA in the U.S.).
- Safety and monitoring
- JAK inhibitors carry risks: serious infections (including TB and herpes zoster), blood clots, lipid changes, liver enzymes abnormalities, anemia, etc.
- They are generally used under close medical supervision with regular lab tests (CBC, CMP/LFTs, lipids) and infection screening (TB, hepatitis B/C as indicated).
- They may not be suitable for everyone (e.g., pregnancy, certain infections, cardiovascular risk factors, or a history of certain cancers).
- If stopped, hair loss can sometimes resume.
- Practical considerations
- Dosing for AA (if used off-label) would be determined by a dermatologist and may differ from RA dosing.
- Insurance coverage for off-label use can be challenging; cost is a factor.
- Topical JAK inhibitors (not Xeljanz) and other AA treatments (steroids, topical immunotherapy, etc.) are often tried first, depending on disease severity and extent.
If you’d like, I can:
- Check the latest regulatory status for your country/region.
- Summarize the most recent AA-specific studies on JAK inhibitors.
- Help you prepare questions to discuss with a dermatologist.
Would you like me to look up current approvals where you are or tailor the information to your situation (age, extent of AA, prior treatments)?